Delving into the Latest Updates on Lansheng Biomedical (Suzhou) Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Cardiovascular Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	2

Top 5 Drug Type	Count

Small molecule drug	2

Top 5 Target	Count

PDE4(Phosphodieterase 4)	1
PI3Kγ x PI3Kδ	1

试验旨在研究单次空腹和餐后口服兰晟生物医药（苏州）有限公司研制、永信药品工业（昆山）股份有限公司生产的盐酸度洛西汀肠溶胶囊（60 mg）的药代动力学特征；以LILLY DEL CARIBE, INC. 生产的盐酸度洛西汀肠溶胶囊（Cymbalta®，60 mg）为参比制剂，比较两制剂的药动学参数Cmax、AUC0-t、AUC0-∞，评价两制剂的人体生物等效性。

[Translation]

The study aimed to study the pharmacokinetic characteristics of duloxetine hydrochloride enteric-coated capsules (60 mg) developed by Lansheng Biopharmaceuticals (Suzhou) Co., Ltd. and produced by Yongxin Pharmaceutical Industry (Kunshan) Co., Ltd. after single fasting and postprandial oral administration; duloxetine hydrochloride enteric-coated capsules (Cymbalta®, 60 mg) produced by LILLY DEL CARIBE, INC. were used as the reference preparation, and the pharmacokinetic parameters of the two preparations, including Cmax, AUC0-t, and AUC0-∞, were compared to evaluate the bioequivalence of the two preparations in humans.

Start Date13 May 2020

Sponsor / Collaborator

Lansheng Biomedical (Suzhou) Co., Ltd.

100 Clinical Results associated with Lansheng Biomedical (Suzhou) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Lansheng Biomedical (Suzhou) Co., Ltd.

Login to view more data

100 Deals associated with Lansheng Biomedical (Suzhou) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Lansheng Biomedical (Suzhou) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 09 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

Login to view more data